Skip to main content
OpenTrials
Completed

NCT Number: NCT06971484

Glucosamine Sulfate Bioavailability

This study aims to compare the pharmacokinetics and bioavailability of crystalline glucosamine sulfate and regular glucosamine sulfate using a double-blind, randomized, crossover design.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bioavailability and Pharmacokinetics

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ISURA

Burnaby, British Columbia, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female aged 21- 65 years
  • Healthy, good physical condition
  • Voluntary, written, informed consent to participate in the study.

Exclusion criteria

  • Serious acute or chronic diseases e.g. liver, kidney, or gastrointestinal diseases
  • Use of medications affecting glucosamine metabolism
  • Known allergies to shellfish or glucosamine
  • Pregnancy or breastfeeding
  • Participation in another investigational study

Treatment and study plan

Crystalline glucosamine sulfate

Dietary Supplement

A maximum single dose of 1500mg of glucosamine sulfate in a caplet.

Regular glucosamine sulfate

Dietary Supplement

A maximum single dose of 1500mg of glucosamine sulfate in hard gel capsules.

Primary outcomes

  1. AUC: the area under the concentration-time curve

    Time frame: 0 (baseline; pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 hours (post-dose)

    To determine the gastrointestinal absorption of orally ingested glucosamine sulfate in healthy adult volunteers and compare the Area under the plasma concentration versus time curve (AUC) with that of other capsules containing glucosamine sulfate.

  2. Cmax: maximum plasma concentration

    Time frame: 0 (baseline; pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 hours (post-dose)

    To determine the gastrointestinal absorption of orally ingested glucosamine sulfate in healthy adult volunteers and compare the peak plasma concentration (Cmax) with that of other capsules containing glucosamine sulfate.

  3. Tmax: the time point of maximum plasma concentration

    Time frame: 0 (baseline; pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 hours (post-dose)

    To determine the gastrointestinal absorption of orally ingested glucosamine sulfate in healthy adult volunteers and compare the time point of maximum plasma concentration (Tmax) with that of other capsules containing glucosamine sulfate.

Sponsors and collaborators

Lead sponsor

Isura

Other

Registry information

Official study title

Comparative Bioavailability of Crystalline and Regular Glucosamine Sulfate: A Randomized Crossover Study in Healthy Adults

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
May 14, 2025
Registry last updated
May 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.